Decoy Therapeutics (DCOY)
NASDAQ:DCOY
DCOY Stock Chart & Stats
$6.07
-$0.06(-3.48%)
At close: 4:00 PM EST
$6.07
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$5.40 - $416.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$3.11M
Enterprise Value-$7.41M
Total Cash (Recent Filing)$10.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-2.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.87
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$2.50Price Target Upside-58.81% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved CapitalizationNear-zero debt and a sharp equity rebound in 2025 materially reduce financial fragility. Lower leverage increases flexibility to fund R&D or partner programs without immediate refinancing, improving the company’s ability to advance its pipeline and survive funding cycles over the medium term.
Diversified Funding And Strategic PartnersAccess to institutional investors plus non-dilutive programs and partnerships (e.g., BARDA, Google AI program, NVIDIA Inception) provides structural resources and external validation. Such funding and collaborations reduce reliance on equity raises and strengthen capabilities to progress preclinical work.
Regained Nasdaq Listing ComplianceFormal restoration of Nasdaq compliance preserves public listing status and access to capital markets, supporting the company’s ability to raise follow-on financing or use stock-based incentives. This reduces immediate existential listing risk and aids medium-term strategic flexibility.
Bears Say
Absent Sustained RevenueThe lack of sustained revenue limits operating leverage and obscures a commercial path. Without predictable product income, the company must rely on external financing to support operations and trials, reducing visibility to profitability and constraining long-term planning and reinvestment.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow creates ongoing funding needs and elevates dilution risk. Continued cash burn forces prioritization of programs, can delay trials or development milestones, and makes execution contingent on securing additional capital within the next several quarters.
Listing Vulnerability Under Mandatory MonitoringAlthough compliance was regained, the one-year Mandatory Panel Monitor means any recurrence of bid-price weakness could lead to automatic delisting proceedings. This conditional vulnerability heightens investor uncertainty and could impair access to public capital if operational setbacks occur.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $5.40 and its highest was $416.05 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $3.11M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 531,968 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Cambridge, MA.
DCOY Stock 12 Month Forecast
Average Price Target
$2.50
▼(-58.81% Downside)
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Ownership Overview
4.73% Insiders
0.18% Mutual Funds
― Other Institutional Investors
95.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---